Mendelics Análise Genômica

What Mendelics Análise Genômica does

Mendelics Análise Genômica is a privately held Brazilian genomic diagnostics laboratory founded in 2012 and headquartered in São Paulo. The company provides genetic and genomic testing services using Next Generation Sequencing (NGS) technology, paired with a proprietary artificial intelligence software for variant interpretation and clinical reporting. Its test menu spans exome sequencing, hereditary cancer panels, polygenic risk scores for breast cancer, carrier screening for recessive and X-linked diseases, expansion screening, and specialty panels covering 12 medical areas (cardiology, dermatology, endocrinology, gastroenterology, medical genetics, hematology, nephrology, neurology, ophthalmology, oncology, otolaryngology, and women's health). The company reports having processed more than 100,000 genetic tests, which it states constitutes the largest database of Brazilian and Latin American genetic variants. Mendelics also markets a direct-to-consumer cheek swab test (Teste da Bochechinha) covering more than 300 diseases.

The company operates a B2B2C model in which medical specialists prescribe tests, with sample collection performed at two São Paulo facilities (one patient service center at Av. Nove de Julho and one technical-operational center at Av. Braz Leme). Pricing is quote-based and not publicly disclosed; revenue is generated on a per-test basis, covered either by major Brazilian health insurance operators (convênios such as Bradesco Saúde, SulAmérica, and Amil) or by direct out-of-pocket patient payment. A Colombia contact line indicates early Latin American cross-border activity.

Mendelics positions itself as the first and largest genomic analysis laboratory in Latin America, holding five accreditations that it states no other genomic lab in the region holds: CAP (College of American Pathologists), PALC, ISO 15189 (via CGCRE/Inmetro), CLIA, and ISO 27001 (information security). Its proprietary AI analysis software received an MIT Innovation Award. Leadership comprises CEO David Schlesinger, VP of Business Development André Valim, Medical Director Dr. Fernando Kok (also listed as the technical responsible, CRM-SP 32.255), and Director of Bioinformatics João Paulo Kitajima.

Name

Mendelics Análise Genômica

Legal name

Mendelics Análise Genômica

Website

https://mendelics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Mendelics Análise Genômica is a São Paulo-based genomic diagnostics laboratory using Next Generation Sequencing and proprietary AI software to deliver genetic tests (exome, cancer panels, carrier screening, PRS) to physicians and patients in Brazil and Latin America.

Ownership category

akta.pro rank

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Genetic Testing Services: One-time diagnostic genetic tests billed per examination. Services covered by Brazilian health insurance plans (convênios) or paid directly by patients. Test menu includes exome, cancer panels, carrier screening, and specialty panels.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Mendelics Análise Genômica is a clinical genomic laboratory that performs diagnostic genetic testing on biological materials and provides clinical interpretation. It processes exome sequencing, hereditary cancer panels, carrier screening, polygenic risk scores, and specialty panels across twelve medical areas, leveraging Next Generation Sequencing (NGS) and a proprietary AI-powered analysis platform to deliver variant interpretation reports to prescribing physicians and patients.

Product overview

Mendelics Análise Genômica offers a portfolio of genetic and genomic testing products and services. The core offerings include: Exoma Mendelics (comprehensive exome sequencing with highest diagnostic rate), Exames Genéticos para Câncer (cancer genetic tests including hereditary cancer panels and PRS for breast cancer), Teste da Bochechinha (cheek swab test covering 300+ diseases), Triagem de Portador (carrier screening for recessive diseases), Painel NGS para Triagem de Expansões (expansion screening), and specialty panels across 12 medical areas (Cardiology, Dermatology, Endocrinology, Gastroenterology, Medical Genetics, Hematology, Nephrology, Neurology, Ophthalmology, Oncology, Otolaryngology, Women's Health). All tests are powered by proprietary AI software for genetic data analysis. The company is the first and largest genomic analysis laboratory in Latin America.

Differentiator

Problem solved

Functional benefit

Products and services

• Exoma Mendelics Comprehensive whole-exome sequencing test analyzing the entire exome with the highest diagnostic rate in the market. Intended for physicians and patients requiring broad genetic diagnosis for rare or complex conditions.
• Exames Genéticos para Câncer (Cancer Genetic Tests) Suite of genetic tests for cancer analysis and hereditary cancer risk assessment. Targets oncology specialists and patients with suspected hereditary cancer risk.
• Teste da Bochechinha Cheek swab DNA test analyzing more than 300 diseases in a single examination. Marketed as an accessible test for parents and individuals seeking broad genetic screening through an easy collection method.
• Triagem de Portador de Mutações de Doenças Recessivas e Ligadas ao X Carrier screening test for recessive and X-linked disease mutations, aimed at individuals and couples evaluating reproductive risk of hereditary conditions.
• Painel de Câncer Hereditário Padrão-Ouro Comprehensive hereditary cancer panel marketed as the gold standard for cancer risk assessment, intended for oncology specialists, geneticists, and at-risk patients.
• Análise Poligênica (PRS) para Câncer de Mama Polygenic Risk Score (PRS) analysis evaluating breast cancer susceptibility, targeted at women's health specialists and patients seeking personalized breast cancer risk assessment.
• Painel NGS para Triagem de Expansões Next Generation Sequencing (NGS) panel for screening genetic expansions, intended for neurologists and geneticists diagnosing expansion-related disorders.
• Exames Genéticos para Nefrologia Genetic tests tailored for nephrology conditions, aimed at nephrologists diagnosing hereditary kidney disease.

Quantifiable outcome

• Highest diagnostic rate in the market for exome testing

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Quest Diagnostics: One of the largest US clinical laboratory networks with an extensive genetic and molecular diagnostics menu. Comparable as a full-service clinical lab with genomics capabilities, though not a pure-play and operating at far greater scale with US-centric payor relationships.
• Laboratory Corporation of America (Labcorp): Global clinical laboratory network offering comprehensive genetic and genomic testing services. Comparable in broad payor-reimbursed genetic testing menu, B2B2C physician channel, and CLIA-certified lab infrastructure.
• Dasa (Diagnósticos da América): Brazil's largest clinical diagnostics network, offering genomic and molecular testing alongside routine lab work. Comparable as a Brazil-based clinical laboratory with genetic/molecular diagnostics capabilities, though Dasa operates a vastly broader portfolio and is not a pure-play genomics specialist.
• Grupo Fleury: Major Brazilian clinical diagnostics company with a strong specialty and genetics offering. Comparable in operating model (B2B2C, convênio-reimbursed, hospital/physician channel) and Brazilian footprint, but broader in scope than Mendelics' pure-play genomics focus.

Direct peers

• Invitae: US-based genetic testing company offering exome, cancer panels, and carrier screening with AI-assisted interpretation. Closely comparable in product menu (exome, hereditary cancer, reproductive health) and B2B2C distribution through physicians, though operating at much larger scale and with multi-payor US infrastructure.
• Color Genomics: Genetic testing company offering hereditary cancer, pharmacogenomics, and population health programs. Comparable in polygenic risk scores, employer/health-plan partnerships, and NGS-based hereditary panels, with overlapping product roadmap.
• Myriad Genetics: US-based pioneer in hereditary cancer and pharmacogenomic testing. Comparable in oncology-focused genetic panels and proprietary variant interpretation software, with similar payor-reimbursement-driven business model in hereditary cancer risk assessment.

Emerging players

• 23andMe: Direct-to-consumer genetic testing company with hereditary risk and pharmacogenomics reports. Comparable in genetic test consumer marketing and broad-panel philosophy, though distinct in DTC-first distribution versus Mendelics' physician-channel model.
• Centogene: Germany-based rare disease genomics company with proprietary variant database for under-studied populations. Comparable in rare-disease focus, AI-supported variant interpretation, and positioning around non-European reference data — a directly analogous data moat thesis.

Regional players

• Sabin Diagnóstico e Saúde: Brazilian clinical diagnostics group with specialty testing including molecular and genetic tests. Comparable as a Brazil-based clinical lab with convênio reimbursement and physician channel, operating at significant scale but with broader diagnostic offering than Mendelics' pure-play genomics positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/mendelics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mendelics Análise Genômica